Opportunities and challenges for antisense oligonucleotide therapies by Kuijper, E.C. (Elsa C.) et al.
R E V I EW AR T I C L E
Opportunities and challenges for antisense oligonucleotide
therapies
Elsa C. Kuijper1 | Atze J. Bergsma2,3 | W.W.M. Pim Pijnappel2,3 |
Annemieke Aartsma-Rus1
1Department of Human Genetics, Leiden
University Medical Center, Leiden, The
Netherlands
2Department of Pediatrics, Center for
Lysosomal and Metabolic Diseases,
Erasmus Medical Center, Rotterdam, The
Netherlands
3Department of Clinical Genetics, Center
for Lysosomal and Metabolic Diseases,
Erasmus Medical Center, Rotterdam, The
Netherlands
Correspondence
Annemieke Aartsma-Rus, LUMC
Postzone S4-P, Albinusdreef 2, 2333 ZA
Leiden, The Netherlands.
Email: a.m.rus@lumc.nl
Communicating Editor: Carla E. Hollak
Abstract
Antisense oligonucleotide (AON) therapies involve short strands of modi-
fied nucleotides that target RNA in a sequence-specific manner, inducing
targeted protein knockdown or restoration. Currently, 10 AON therapies
have been approved in the United States and Europe. Nucleotides are chem-
ically modified to protect AONs from degradation, enhance bioavailability
and increase RNA affinity. Whereas single stranded AONs can efficiently
be delivered systemically, delivery of double stranded AONs requires
capsulation in lipid nanoparticles or binding to a conjugate as the uptake
enhancing backbone is hidden in this conformation. With improved chem-
istry, delivery vehicles and conjugates, doses can be lowered, thereby reduc-
ing the risk and occurrence of side effects. AONs can be used to knockdown
or restore levels of protein. Knockdown can be achieved by single stranded
or double stranded AONs binding the RNA transcript and activating
RNaseH-mediated and RISC-mediated degradation respectively. Transcript
binding by AONs can also prevent translation, hence reducing protein
levels. For protein restoration, single stranded AONs are used to modulate
pre-mRNA splicing and either include or skip an exon to restore protein
production. Intervening at a genetic level, AONs provide therapeutic
options for inherited metabolic diseases as well. This review provides an
overview of the different AON approaches, with a focus on AONs developed
for inborn errors of metabolism.
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1 | INTRODUCTION
Antisense oligonucleotide (AON) therapies are coming of
age; currently 10 AONs have been approved by the Food
and Drug Administration (FDA, USA), and/or the
European Medicines Agency (EMA) and/or the Japanese
Ministry of Health, Labour and Welfare, the majority of
which obtained marketing authorization in the past
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TABLE 1 Overview of approved antisense oligonucleotide drugs
Compound Disease (OMIM number) Mechanism of action Delivery route
Approved
by (when) Reference
Fomivirsen CMV-induced retinitis (NA) Formivirsen binds to UL123 transcripts
and prevents translation into IE2
protein
Intraocular FDA (1998),
EMA (1999)
1
Mipomirsen Familial hypercholesterolemia
(607748)
Mipomirsen binds to ApoB-100
transcripts and induces RNase H
mediated cleavage of targeted
transcripts
Subcutaneous FDA (2013) 2
Eteplirsen Duchenne muscular dystrophy
(310200)
Eteplirsen binds to exon 51 in
pre-mRNA DMD transcripts, thus
preventing inclusion in mature
mRNA; this restores the reading
frame allowing the production of
partially functional dystrophin
protein
Intravenous FDA (2016) 3
Nusinersen Spinal muscular atrophy types I,
II and III (25330, 253550,
253400)
Nusinersen binds to an intronic splicing
silencer in SMN2 pre-mRNA, thus
enhancing SMN2 exon 7 inclusion
and increasing production of SMN
protein
Intrathecal FDA (2016)
EMA (2017)
4
Inotersen Hereditary
transthyretin-mediated
amyloidosis (105210)
Inotersen binds to hATTR transcripts
and induces RNase H mediated
cleavage, thus reducing
thransthyretin protein production
Subcutaneous FDA (2018)
EMA (2018)
5
Patisiran Hereditary
transthyretin-mediated
amyloidosis (105210)
Patisiran is incoorporated into the RISC
complex and induces si-RNA
mediated reduction of hATTR
transcripts and thransthyretin protein
production
Intravenous FDA (2018)
EMA (2018)
67
Volanesorsen Hypertriglycidemia (145750),
familial chylomicronemia
syndrome (118830) and
familial partial lipodystrophy
(151660)
Volanesorsen binds to apolipoprotein
C-III transcripts and induces RNase
H induced cleavage and reduced
protein formation; used in
combination with low fat diet
Subcutaneous EMA (2019) 8
Givosiran Acute hepatic porphyrias
(612740 and 176000)
Givosiran is incorporated into the RISC
complex and induces si-RNA
mediated reduction of ALAS1
transcripts and reduced formation of
toxic heme intermediates
Subcutaneous FDA (2019) 9
Golodirsen Duchenne muscular dystrophy Golodirsen binds to exon 53 in
pre-mRNA DMD transcripts, thus
preventing inclusion in mature
mRNA; this restores the reading
frame allowing the production of
partially functional dystrophin
protein
Intravenous FDA (2019)
Viltolarsen Duchenne muscular dystrophy Viltolarsen binds to exon 53 in
pre-mRNA DMD transcripts, thus
preventing inclusion in the mature
mRNA; this restores the reading
frame allowing the production of
partially functional dystrophin
Intravenous Japanese
Ministry for
Health,
Labour and
Welfare (2020)
10
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4 years (Table 1). This therapeutic approach uses small
pieces of modified DNA or RNA that are synthesized
from chemically modified nucleotides.11,12 They target
RNA in a sequence specific manner through Watson-
Crick base pairing, and can induce targeted protein
knockdown or protein restoration. Compared to chemical
compounds, antisense oligonucleotide therapies have
unprecedented specificity, for example, they provide the
possibility to target specific transcript isoforms or a spe-
cific member in a family of closely related proteins.
Because they intervene at a genetic level, they provide
therapeutic options particularly for inherited diseases. In
this review we will give a high level overview on thera-
peutic AONs, including modifications needed to endow
them with drug-like properties, delivery and safety con-
siderations, and provide examples of currently approved
antisense oligonucleotides. Finally, we will outline how
these modalities have been explored to treat inherited
metabolic diseases.
2 | ANTISENSE
OLIGONUCLEOTIDE DRUG
CONSIDERATIONS
2.1 | Chemical modifications
Therapeutic AONs are generally 15-30 nucleotides long
and can be single or double-stranded moieties. Short DNA
and RNA molecules are very sensitive to degradation by
endo- and exonucleases. As such, AONs require chemical
modifications to increase nuclease resistance.11,13 These
modifications can also provide additional benefits to the
AONs, such as increased affinity to the target transcripts
or improved bioavailability. Many different chemical mod-
ifications are currently available. The first and most widely
used modification is the phosphorothioate (PS) modifica-
tion, where an oxygen in the AON backbone is replaced
by a sulfur atom.14 Although this modification reduces the
affinity of the AON to its target, it improves stability,
uptake and bioavailability. AONs are compounds of inter-
mediate molecular weight (5-12 kDa), meaning they are
small enough to be filtered out by the kidney. AONs with
a PS backbone will, however, bind serum proteins with
low affinity, thus preventing renal clearance and improv-
ing uptake by other organs after systemic delivery, in par-
ticular the liver.
Additional modifications to the sugar ribose (20O-
methyl and 20O-methoxyethyl, 2OMe and MOE, respec-
tively) increase affinity to the target RNA and reduce
some of the PS induced toxicity (see below). Finally, some
modifications change the whole nucleotide, such as the
phosphorodiamidate morpholino oligomers (PMO) or
peptide nucleic acids (PNA). These modifications show
little resemblance to the original nucleotides and as such
are not recognized by, for example, nucleases. However,
they maintain the ability to target transcripts in a
Watson-Crick manner. Which modifications to use varies
depending on the AON modality used and the target
tissue,11-13,15 as we describe later.
2.2 | Delivery
For single stranded AONs with a PS backbone systemic
delivery is feasible. The majority of AON will be taken up
by liver and kidney, but some uptake by most other tissues
is occurring, with the exclusion of the nervous system, as
most AON chemistries are unable to cross the blood-brain
barrier. An exception is the tricyclo-PS modification, where
a minute amount of compound appears to reach the
central nervous system (CNS) when large amounts are
injected systemically.16 Notably, after local delivery of sin-
gle stranded MOE-PS AONs to the CNS, intra-
cerebroventricular in mice and intrathecal in non-human
primates and humans, these AONs are rapidly taken up by
the neurons and distribute throughout the CNS.17,18 For
systemic delivery of single stranded AONs often a frequent
dosing regimen is used with multiple injections per month.
By contrast, the half-life of AONs in the CNS is much lon-
ger; in the order of months in non-human primates and
humans, which enables less frequent treatment.
For double stranded AONs delivery is more challeng-
ing. The PS backbone is sheltered in the double stranded
composition, thus limiting its potency as an uptake
enhancer. However, it has been possible to have efficient
uptake by hepatocytes through capsulation of double
stranded AONs in lipid nanoparticles.19 Even more effi-
cient liver uptake can be achieved with the GalNac con-
jugate.20 This binds specifically to the asialoglycoprotein
receptor that is highly abundant on liver cells, and able
to generate receptor-mediated uptake of its ligand quickly
and efficiently, with a recycle time of ~15 minutes.
2.3 | Safety
There are two types of safety considerations for AON
therapies. First, there are sequence specific safety aspects.
For AON strategies aiming at protein knockdown, exag-
gerated pharmacology can be an issue, where too much
knockdown of the target transcripts and encoded proteins
in the target tissue, or the nontarget tissue can lead to
undesired effects. In addition, it is possible that the AON
binds to nontarget transcripts. The latter can often be
avoided using in silico screening to confirm uniqueness
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of the AON target in the human genome or trans-
criptome. However, some AON chemistries have a very
high affinity for RNA, and may also bind promiscuously
to other transcripts, despite one or more mismatches.
Searching for a target sequence that is as unique as possi-
ble can reduce this risk.
The second safety aspect is related to the chemical
modifications of the AONs.11,12 Different modifications
have their own safety profile, where AONs of the same
chemistry often behave as a class, with the exceptions of
some motifs that are known to induce an immune
response through activation of Toll-like receptors.21 Often
CpG motifs are involved in this, and methylating the “C”
nucleotides of the AONs generally negates this effect to a
great extent.22,23 Furthermore, one can screen for the
occurrence of these effects in vitro, thus deselecting
AONs that induce an immune response.
Overall, the PS backbone is the main driver of toxic-
ity. For a more elaborate outline of these effects we refer
the reader to review papers on this topic.24,25 In sum-
mary, through specific binding of serum proteins AONs
with a PS backbone can inhibit coagulation
(by inhibition of the tenase pathway) and activate com-
plement (through Factor H binding).25-27 In addition,
there are safety findings related to sites where AONs
accumulate, that is, liver, kidney, and lymph nodes.24
Proteinuria is frequently observed in patients who are
treated systemically and chronically with AONs, probably
due to accumulation of AONs in the proximal tubuli,
sometimes inducing apoptosis and hence interfering with
protein reabsorption. In the liver AONs are mainly taken
up by the Kupffer cells and hepatocytes. In lymph nodes
AON accumulation can result in an inflammatory
response. Subcutaneous delivery of PS-modified AONs
result in injection site reactions due to an as yet
unknown mechanism. Finally, in a subset of patients
thrombocytopenia has been reported to occur,24,28
resulting in hospitalization of patients and possibly death
for one patient.5 This risk of thrombocytopenia appears
to be sequence and dose dependent.29 With improved
chemistry, delivery vehicles and conjugates, patients can
now be dosed a lower levels, thus reducing the risk and
occurrence of side effects.
3 | HOW TO EXPLOIT ANTISENSE
OLIGONUCLEOTIDE DRUGS FOR
GENETIC DISEASES
AONs can be used to modulate gene expression by
targeting transcripts. First, AONs can be used to achieve
targeted knockdown of a toxic protein or a key protein in
a pathological pathway (Figure 1). It is also possible to
restore production of a missing protein by AON-induced
splicing modulation (Figure 2). Notably, as a genetic ther-
apy approach AONs differ in several ways from gene
addition approaches. First, AONs target gene transcripts,
while with gene therapy, generally cDNA of a missing or
mutated gene is provided. Due to turnover of AONs,
effects are transient, while for gene addition therapies
generally effects have a more permanent nature. AONs
are short, synthetic pieces of modified RNA or DNA,
which are mostly delivered without an excipient. Gene
addition therapies mostly rely on viral vectors to deliver
transgenes that can be thousands of bp long.
Here we will outline the different AON modalities
focusing on those that have been marketed so far.
3.1 | Protein knockdown
Single stranded AONs can induce targeted knockdown of
transcripts by activating RNase H, an enzyme that cleaves
DNA:RNA hybrids30(Figure 1B). Since RNase H-mediated
cleavage is initiated at the 20 position of the ribose, modifi-
cations at this position (eg, 2OMe, MOE) or modifications
that significantly alter the nucleotide structure (eg, PMO,
PNA) render AONs RNase H resistant. To still benefit from
the increased affinity of the modified nucleotides, generally
a gapmer AON is used, with a PS stretch in the middle that
initiates RNase H cleavage, flanked by more modified
nucleotides at both ends (Figure 1B). Examples of RNase H
AONs are mipomersen and volanesorsen (Table 1).8,31
These bind to Apo-B 100 and apolipoprotein C-III tran-
scripts, respectively, which are both highly expressed in
liver, one of the main target organs after systemic AON
delivery. Subcutaneous treatment with mipomersen and
volanesorsen has resulted in a significant reduction in cho-
lesterol or triglyceride levels in blood of patients with famil-
ial high cholesterolemia or triglyceridemia, respectively.
Mipomersen was approved in 2013 by the FDA, but was
discontinued in 2018 due to limited clinical effects and
safety concerns related to its hepatotoxicity.32
Double stranded siRNAs are another tool to achieve
transcript knockdown33 (Figure 1C). siRNAs “hijack” the
RNA-induced silencing complex (RISC), where the guide
strand of the siRNA is incorporated into the RISC and
binds specifically to the target, which is then degraded.
RISC induced silencing is a catalytic process and some
siRNAs have been shown to result in functional effects
that persists for months after treatment.34 The guide
strand generally cannot be chemically modified, because
this interferes with incorporation into the RISC complex.
However, the opposite strand (passenger strand) does tol-
erate chemical modifications, to ensure stability of the
siRNA.
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Currently, two siRNA AON has been approved,
patisiran and givosiran.7 Patisiran is an siRNA that tar-
gets transthyretin transcripts as a therapy for hereditary
transthyretin (hATTR)-mediated amyloidosis. These
patients have variants in the TTR gene that lead to aggre-
gation of transthyretin protein, resulting in a mul-
tisystemic disorder that includes polyneuropathy and
cardiac problems. The primary expression site for trans-
thyretin is liver hepatocytes. As mentioned, delivery of
double stranded siRNAs to any tissue is challenging.
Therefore, a lipid nanoparticle formulation is used to
ensure sufficient patisiran delivery to and uptake by
hepatocytes. In a clinical trial intravenous treatment
with patisiran resulted in a significant and clinically
relevant reduction of polyneuropathy.6 Notably,
inotersen is a single stranded RNase H cleavage induc-
ing AON that targets the same transcript as patisiran.
Subcutaneous delivery of inotersen has also been
approved by FDA and EMA for treatment of hATTR-
mediated amyloidosis based on a slower disease pro-
gression and improved quality of life for treated
patients compared to placebo.5
FIGURE 1 AON-mediated protein knockdown. A, The pre-mRNA transcribed from the DNA is spliced and capped to obtain the final
mRNA, which is exported to the cytoplasm and translated into protein at the ribosomes. B, As the single stranded AON binds to the mRNA,
this complex is recognized and degraded by RNaseH, an endonuclease present in nucleus and cytoplasm, blocking protein production. C,
From the double stranded siRNA, the guide strand is incorporated into the RNA-induced silencing complex (RISC). This complex
specifically binds the targeted mRNA, inducing its degradation and inhibiting protein production. D, The AON binds the mRNA, thereby
changing its conformation, preventing the formation of the ribosome and blocking the process of protein translation
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FIGURE 2 Schematic depiction of AON-mediated protein restoration strategies using on disease examples. A, Exon inclusion.
Normally, the majority of SMN2 transcripts does not include exon 7 which prevents the production of functional protein. By blocking an
intronic splice silencer that prevents recognition of exon 7, AON treatment stimulates the inclusion of exon 7 and thereby production of
functional protein. B, Exon skipping. The deletion of exons 49 and 50 disrupts the DMD open reading frame leading to a premature stop
codon. AON-mediated skipping of exon 51 restores the reading frame and allows production of partially functional protein. C, Restoring
pseudoexon inclusion. When a variant creates a novel intronic cryptic splice site, a pseudoexon can be included in the CLN7 transcript.
Blocking of this cryptic splice site by AONs restores normal splicing. D, Restoring partial intron retention. A variant-induced intronic cryptic
splice site leads to partial intron retention of FECH as this splice site is now used as splice acceptor site. Blocking of the cryptic splice
acceptor site restores normal splicing. E, Restoring cryptic splicing. In case of a variant-induced exonic cryptic splice site as in IDS, part of
the exon is excluded as the cryptic splice site is used. AON treatment prevents the used of the cryptic splice site and stimulates use of the
canonical splice site. F, Modulating alternative splicing. A variant in GAA silences the normal splice acceptor site of exon 2, thereby
enabling the inclusion of a natural pseudoexon. Blocking of the pseudoexon splice sites with AONs restores normal splicing. G, Another way
to prevent the inclusion of a pseudoexon in GAA is by strengthening the canonical splice sites of exon 2 by blocking of exonic splice
silencers in exon 2 with AONs. Note this figure shows several but limited examples of protein restoring strategies. Star, variant; triangle,
cryptic splice site
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Acute hepatic porphyria (OMIM#612740) is an
inherited metabolic disorder caused by variants in the
ALAD gene, that encodes the protein porphobilinogen
synthase, a protein involved in hepatic heme synthesis.
Defects in this gene results in accumulation of heme
intermediates. Givosiran is an siRNA that targets delta
aminolevulinic acid synthase 1 (ALAS1) transcripts,
which reduces the production of toxic intermediates. In a
clinical trial, subcutaneous givisoran treatment resulted
in a significant reduction of porphyria attacks in treated
patients, thus far without any sign of heme deficiency.9
Givisoran is the first approved oligonucleotide carrying a
GalNac conjugate.
3.2 | Protein restoration
Single stranded AONs that are fully RNase H resistant
can be used to modulate pre-mRNA splicing, the process
where introns are removed from gene transcripts, and
exons are joined to form the mRNAs35 (Figure 2).
The most notable example of a splice modulating is
the exon inclusion achieved by nusinersen (Figure 2A),
an intrathecally delivered MOEPS modified AON that is
approved for all types of spinal muscular atrophy (SMA),
a set of diseases characterized by the progressive loss of
motorneurons and motorfunction, ranging from very
severe (type I) to severe (type III) to the milder SMA type
IV.36 SMA type I patients never are able to sit indepen-
dently and generally die before the age of 2 years. SMA
types II and III have a later onset and patients are origi-
nally able to sit (type II) or stand (type III), but also here
patients suffer from progressive loss of motorneurons and
motor function. Type IV is a rare, adult-onset form of the
disease with a milder progression. SMA is caused by vari-
ants in the SMN1 gene that abolish production of survival
motorneuron (SMN) protein.37 Complete lack of SMN is
embryonically lethal. Primates carry a homologous
SMN2 gene, which allows the production of low levels of
SMN protein. While the SMN1 and SMN2 genes are
almost identical, small variations cause SMN2 exon 7 to
be very poorly recognized by the splicing machinery.
Thus, only 10% of the transcripts include exon 7 and
allow production of stable SMN protein. There is copy
number variation for SMN2, and the number of SMN2
gene inversely correlates with the severity of SMA.36
Nusinersen is an AON that binds to intron 7 of SMN2
transcripts and thereby facilitates recognition and mRNA
inclusion of exon 7 by the splicing machinery. Because
SMA primarily affects the motorneurons, delivery to the
nervous system is required. Intrathecal delivery of
nusinersen has been tested in double-blind, randomized
placebo-controlled clinical trials with SMA types 1 and II
patients and in each case the primary endpoint was
met already during interim analysis.38,39 For SMA type I
this involved event free survival, which was significantly
increased compared to sham treated patients, while for
SMA type II, the motor score was significantly improved
compared to baseline, while for sham treated patients it
declined. Since all types of SMA are characterized by pro-
gressive and irreversible loss of motorneurons, earlier treat-
ment would be preferred. A currently ongoing trial where
SMA patients are treated presymptomatically indeed sug-
gests that earlier treatment results in more significant thera-
peutic effects.40 Recently, also an adeno-associated viral
vector-mediated gene therapy (onasemnogene abeparvovec,
tradename Zolgensma) has been approved for treatment of
SMA patients by FDA and EMA. Now that multiple thera-
pies are available for this disease and in light of the prefer-
ence for early treatment, efforts to implement neonatal
screening for SMA are ongoing in various countries.41
Splice modulating AONs can also be used to induce
exon skipping, that is, remove an exon from the mRNA
transcript42 (Figure 2B). Duchenne muscular dystrophy
(DMD) is an early onset, severely progressive muscle
wasting disease, caused by variants in the DMD gene that
cause premature truncation of dystrophin protein transla-
tion. Dystrophin provides muscle fibers with stability by
connecting the actin cytoskeleton to the extracellular
matrix. Individuals with variants that do not disrupt the
open reading frame, allowing the production of internally
deleted dystrophins that maintain their connecting
domains are affected by the less severe Becker muscular
dystrophy. AON-mediated exon skipping can be used to
restore the reading frame of the DMD transcripts, all-
owing them to produce Becker-type, partially functional
dystrophins. This approach is variant specific. However,
most DMD patients carry a large deletion of one or more
exons, which cluster in a hotspot. As such, skipping cer-
tain exons applies to larger groups of patients. AONs
inducing exon 51 skipping, which applies to 14% of
patients, have been developed furthest.42 Because most of
the over 700 skeletal muscles in the human body are
affected by DMD, systemic treatment is required.
Drisapersen, a 2OMePS AON, was evaluated in 300 DMD
patients, and initially showed promising results in young
DMD patients, but a phase 3 trials failed to meet its pri-
mary endpoint (6 minute walking distance) and develop-
ment was abandoned.3 Eteplirsen, a PMO AON has
received accelerated approval by the FDA, based on
minute increases in dystrophin expression. Functional
efficacy has not yet been confirmed and evidence for this
needs to be provided to the FDA by 2021.3 Similarly,
golodirsen and viltolarsen, both PMOs for exon 53 skip-
ping received accelerated approval from FDA and condi-
tional approval from the Japanese Ministry of Health,
KUIJPER ET AL. 7
Labour and Welfare recently, based only on increases in
dystrophin expression, while functional efficacy will need
to be confirmed in the future.
AON-mediated splicing modulation is also a very
appealing approach for cryptic splicing variants (Figure 2C).
These involve intronic variants that result in the inclusion
of an intronic part of the transcript in the mRNA transcript
(pseudo-exon). When these pseudoexons are blocked by
AONs, this may restore normal splicing and protein produc-
tion (Figure 2C). The challenge, however, is that generally
cryptic splicing variants are private, that is, occurring in
only a single patient or family. Nevertheless, proof-of-
concept of the feasibility of developing an AON treatment
for an individual cryptic splicing variant was recently
reported. This involved a patient with neuronal ceroid
lipofuscinosis 7 (a type of Batten's disease, a severe pro-
gressive neurodegenerative disorder, OMIM#610951).43
In this case, the disease was caused by compound het-
erozygous CLN7 variants, including one allele carrying
a variant that resulted in inclusion of a pseudoexon. A
team of researchers and clinicians managed to design
an AON, test it in patient-derived fibroblasts, have
interaction with and advice from FDA and perform the
required toxicity tests in rat, resulting in the initiation
of an N = 1 trial in the patient within a year of diagno-
sis. Currently the patient receives four intrathecal
injections of 42 mg “milasen,” a MOEPS AON, per
year. So far the treatment is tolerated well. Since the
initiation of the treatment functional scores, which
were mainly declining prior to treatment, have mostly
stabilized. Furthermore, a year after treatment onset,
the patients suffers from between 0 and 20 seizures per
day, which last less than a minute, where before treat-
ment, she experienced 15-30 seizures daily, which
lasted 1-2 minutes.
Additional efforts to develop AON therapies for
individual or small groups of patients have been initi-
ated at various locations. It is obviously impossible to
conduct clinical trials for these AONs. Nevertheless, it
will be important to measure efficacy in these patients
in some way, for example, by assessing functional
decline or evaluating whether the missing protein is
restored if this can be measured in an easily accessible
fluid or tissue.
4 | ANTISENSE
OLIGONUCLEOTIDES AS A
POTENTIAL TREATMENT FOR
INHERITED METABOLIC DISEASES
Approved therapies for the metabolic disorders familial
hypercholesterolemia and acute hepatic porphyria have
been discussed above. Clinical trials and preclinical stud-
ies are currently ongoing for the development of AON
therapies for several additional metabolic disorders
(Table 2) (previously reviewed by Perez et al89). These are
discussed in more detail later.
4.1 | Ongoing clinical trials with AONs
for metabolic diseases
AON therapies under development for familial hypercho-
lesterolemia (OMIM#607748) and primary hyperoxaluria
type 1 and type 2 (OMIM#259900 and 260000, respec-
tively) are currently tested in clinical trials.
While Mipomersen is an AON for the treatment of
familial hypercholesterolemia that has been approved by
the FDA, the EMA has not approved the use of this drug
due to cardiovascular complications and heightened enzy-
matic liver values (https://www.ema.europa.eu/documents/
assessment-report/kynamro-epar-public-assessment-report_
en.pdf). These findings warranted the investigation of alter-
native treatments. Currently, an AON aimed at knockdown
PCSK9, which encodes a protein that targets the LDL recep-
tor for lysosomal degradation, is in phase III clinical trials
and shows the ability to reduce cholesterol levels and has
an acceptable safety profile.34,58,59,61,63,64
Primary hyperoxaluria is caused by defects in the
enzyme alanine-glyoxylate aminotransferase (type
1, OMIM#259900) or glyoxylate reductase (type
2, OMIM#260000) leading to overproduction of oxa-
late. This results in severe kidney problems including
calcium oxalate kidney stones, progressive oxalate
nephropathy, and kidney failure. Advanced cases of the
disease show systemic symptoms that can lead to severe
morbidity and may eventually cause death. Knockdown of
HAO1 (type 1) or LDHA (type 2) transcripts, which func-
tion upstream in the oxalate synthesis pathway using
siRNA AONs reduces urinal oxalate content in preclinical
studies, and early phase clinical trials. Phase 3 studies are
currently underway for treatment of patients with primary
hyperoxaluria type 1.82-87
4.2 | Preclinical AON studies for
metabolic diseases
4.2.1 | AON-mediated skipping of
intronic variant-induced pseudoexons
Splice modulating AONs have also been investigated in pre-
clinical studies for inherited metabolic diseases. Interest-
ingly, this mostly concerned studies where intronic disease-
associated variants generated a cryptic splice site that
8 KUIJPER ET AL.
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induced inclusion of a pseudoexon into the mRNA tran-
script. This disease mechanism has been exploited to
develop a new treatment for several disorders based on
blockage of the induced cryptic splice site (Table 2). As an
example, erythropoietic protoporphyria (OMIM#177000)
will be discussed here.49 This disease is caused by reduced
levels of ferrochelatase protein, an enzyme involved in
heme synthesis. When the ferrochelatase levels are below
35% of normal values, photosensitive protoporphyrin IX
accumulates in red erythrocytes, plasma, skin, bile and
feces. The most prominent clinical feature is photosensitiv-
ity. In over 90% of patients, this disease results from the
inheritance of a mutated FECH allele in trans with a hypo-
morphic allele harboring a single nucleotide polymorphism
(SNP) in intron 3. This SNP activates a pseudoexon that is
included in a subset of transcripts. As such only reduced
amounts of functional ferrochelatase protein are produced
from this allele. Interestingly, since the vast majority of
affected patients carry this SNP, a reduction of cryptic splic-
ing should apply to most patients (Figure 2D). An AON
targeting the pseudoexon has been developed and tested in
patient derived cultured cells. It has also been tested in
patient erythrocyte precursor cells, where treated cells
showed a reduction in protoporphyrin IX accumulation.49
Several other metabolic disorders for which AON treat-
ments are under development appear to involve exclusion
of variant-induced pseudoexons to restore normal splicing.
These include 6-pyruvoyl-tetrahydropterin synthase defi-
ciency (OMIM#261600), congenital disorder of glycosyla-
tion type 1a (CDG-1a) (OMIM#212065), Fabry disease
(OMIM#301500), hereditary myopathy with lactic acidosis
(OMIM#255125), methylmalonic aciduria and propionic
acidaemia (OMIM#251000 and 606054, respectively),
Niemann-Pick type C1 (OMIM#257220), and ocular albi-
nism Type I (OMIM#300500) (Table 2).44,48-50,66-68,73,74
This highlights the relatively high prevalence of variant-
induced pseudoexon inclusion as a disease mechanism of
metabolic disorders caused by missplicing. These types of
variants appear to be promising candidates for restoring
canonical splicing using an AON.
4.2.2 | Substrate-reduction therapy using
AONs as a potential treatment for
metabolic disorders
Metabolic diseases including lysosomal storage diseases
are characterized by the accumulation of substrates due
to deficiency of specific metabolic enzymes.90 AON treat-
ments that aim at reducing substrates using knockdown
of genes that are important for production of the sub-
strate, termed substrate reduction therapy (SRT), have
been investigated for several diseases (Figure 1).
Mucopolysaccharidosis type I and III (OMIM#607015
and 252900, respectively) are characterized by the accu-
mulation of the polysaccharide heparan sulphate. Several
studies have investigated the use of AONs to knock down
genes involved in the production of heparan sul-
phate.69,72 For Gaucher disease (OMIM#231000) knock-
down of UDP-glucose ceramide glucosyltransferase
(UGCG) using an siRNA has been tested in an effort to
reduce glycosphingolipid levels.65 SRT has also been
applied for Pompe disease (OMIM#232300), aimed at
reduction of cytoplasmic glycogen by knock down of gly-
cogen synthase to reduce glycogen levels in lysosomes.76
Lastly, SRT for Canavan disease (OMIM#271900), a vacu-
olar leukodystrophy caused by accumulation of N-acetyl-
L-aspartate (NAA), has been developed that utilizes a
gapmer design AON to knockdown a protein involved in
NAA synthesis.47
4.2.3 | Other splice switching
mechanisms utilized for metabolic
disorders
Additional splicing variants for which AONs could be a
treatment strategy have been studied, such as a variant in
the IDS gene that resulted in the generation of a new
splice acceptor site within exon 8 (Figure 2E). Conse-
quently, the first part of exon 8 was not included in the
mRNA, thus abolishing the production of idunorate-
2-sulphatase (IDS) protein and resulting in muco-
polysaccharidosis II, a lysosomal storage disease
(OMIM#309900). Here AON treatment of cells expressing
a minigene system that recapitulated the variant resulted
in two types of transcripts, one where normal splicing
was restored, and one where exon 8 was skipped
completely.70,71 A splice switching AON that utilizes a
similar mechanism has been designed for the treatment
of pyridoxine-dependent epilepsy (OMIM#266100).88
Splice-switching AONs have also been applied as a
therapeutic strategy for Pompe disease. Pompe disease is
a lysosomal storage disorder caused by variants in the
GAA gene, thereby disrupting the production of the
enzyme acid α-glucosidase (GAA), which results in glyco-
gen accumulation throughout the body, leading to pro-
gressive myopathy. Recombinant enzyme replacement
therapy is an approved therapy for Pompe disease, but
this treatments has several drawbacks, including a vary-
ing response to treatment and formation of neutralizing
antibodies. Multiple AONs have been generated to cor-
rect aberrant splicing caused by several different rare var-
iants present in the Pompe population.77 These variants
resulted in utilization of natural or variant-induced cryp-
tic splice sites. The AONs in this study were designed to
12 KUIJPER ET AL.
sterically block these cryptic splice sites, and showed an
increase of canonical splicing in all cases. Although these
AONs look promising, they can only be utilized in a
small part of the Pompe disease population. Most effort
has focused on restoring canonical splicing in patients
with Pompe disease that carry the c.-32-13T>G splicing
variant.78-81 Approximately 80% of Caucasian childhood
and adult onset patients carry this variant in intron
1, which decreases the recognition of the splice acceptor
site of exon 2 by the splicing machinery (Figure 2F,G).
This results in inclusion of an intronic natural
pseudoexon. Since the splice donor site of the natural
pseudoexon is relatively close to the canonical exon
2 acceptor, exon 2 is excluded in the majority (~85%) of
transcripts. Since exon 2 contains the AUG start codon,
these transcripts cannot produce functional protein.
However, these patients can produce low levels of GAA
from the low levels of canonically spliced transcripts,
thus explaining the late onset of the disease. In fibro-
blasts and iPSC-derived myotubes generated from these
patients, it has been possible to almost fully restore exon
2 inclusion using AONs that target the splice sites of the
physiological pseudoexon (Figure 2F). This resulted in
restoration of GAA enzyme activity. In another strategy,
AONs promoted exon 2 inclusion by targeting exon
2 itself, which most likely involve the suppression of
exonic splice silencer elements80,81 (Figure 2G). This
approach may offer an alternative to enzyme replacement
therapy for patients with the c.-32-13T>G splicing variant
in the future.
5 | CONCLUDING REMARKS
AON therapies are coming of age, with multiple
approved drugs and tens of late phase clinical trials ongo-
ing. AON therapies also offer promise for inherited
metabolism diseases. When evaluating whether AON
therapy could be an option for any disease, the target tis-
sue is probably the most important consideration. Effi-
cient delivery is possible for liver, the nervous system and
also for the eye. For other tissues, this is more challeng-
ing. Furthermore, due to turnover and clearance of
AONs, target transcripts and proteins, AONs have only
transient effects and treatment has to be repeated. The
frequency depends on the target tissue, but also the
dynamics of the target transcript and proteins. With other
therapeutic areas are also maturing, such as gene ther-
apy, one now has a choice between therapeutic modali-
ties. Which one is more optimal will have to be
determined on a case by case basis and depends on sev-
eral factors such as target tissue, severity of the disease
and speed of disease progression. For AAV gene therapy
preexisting immunity to the viral vector used would pre-
clude patients from being treated. The older patients are
the higher the chance that they have undergone a natural
AAV infection and thus have already developed anti-
AAV antibodies. For AONs preexisting immunity is not
an issue, although immune resonses to RNA-based treat-
ments should be considered. Gene therapy will generally
restore a missing protein, while with AONs it is possible
to restore a protein, but also to achieve knockdown.
While gene therapy is generally perceived as a one-time
treatment, in some forms like AAV, delivered transgenes
remain cytoplasmic, so they will be lost with turnover of
tissue. Retreatment with AAV is not an option as yet, so
in those cases, AON treatment could be an option once
the therapeutic effects of gene therapy have been lost.
Currently approved AONs mainly target rare diseases
and are expensive. These high costs are not something
specific for AONs, but relate to the fact that development
costs for rare disease drugs are often comparable to those
for common diseases. Since the number of treated
patients is lower, development costs per patients are
higher. Due to the high costs, reimbursement and there-
fore access can be challenging. In addition, in the
European Union, where EMA approved drugs have to be
marketed in each member state individually, the time
between approval and access can be long depending on
the marketing requirements which vary for different
countries. The international rare disease research consor-
tium (IRDiRC) aims to address these and other chal-
lenges facing the rare disease therapy field.91
Many AONs require treatment in a hospital (eg, intra-
thecal and intravenous infusions), which leads to addi-
tional costs and burden to the health care system.
Nevertheless, there are also AONs in development for
common diseases, for example, in a phase 2 study, subcu-
taneous treatment with 300 mg inclisiran, a GalNac-
conjugated siRNA targeting PSK9 can reduce cholesterol
of over 50% for 6 months with only minor side effects.34
If the efficacy and safety can be confirmed in the cur-
rently ongoing phase III study involving 15 000 individ-
uals, inclisiran treatment may offer an alternative to
statins. With 10 approved AONs, 3 of which in the last
6 months, and more AONs being tested in phases II and
III clinical trials with favorable results so far, it seems
that AON therapy is now coming of age as a therapeutic
modality.
CONFLICT OF INTEREST
A. A. R. discloses being employed by LUMC which has
patents on exon skipping technology, some of which has
been licensed to BioMarin and subsequently sublicensed
to Sarepta. As co-inventor of some of these patents A. A.
R. is entitled to a share of royalties. A. A. R. further
KUIJPER ET AL. 13
discloses being ad hoc consultant for PTC Therapeutics,
Sarepta Therapeutics, CRISPR Therapeutics, Summit PLC,
Alpha Anomeric, BioMarin Pharmaceuticals Inc., Eisai,
Astra Zeneca, Santhera, Audentes, Global Guidepoint and
GLG consultancy, Grunenthal, Wave and BioClinica, hav-
ing been a member of the Duchenne Network Steering
Committee (BioMarin) and being a member of the scien-
tific advisory boards of ProQR, Sarepta Therapeutics,
Silence Therapeutics and Philae Pharmaceuticals. Remu-
neration for these activities is paid to LUMC. LUMC also
received speaker honoraria from PTC Therapeutics and
BioMarin Pharmaceuticals and funding for contract
research from Italpharmaco, Zakini and Alpha Anomeric.
E. K., A. B. and W. W. P. P. declare no conflict of interest.
AUTHOR CONTRIBUTIONS
Annemieke Aartsma-Rus and Elsa C. Kuijper generated
an outline for the contents, Annemieke Aartsma-Rus
wrote the manuscript, edited the summary and generated
the tables, Elsa C. Kuijper generated the summary, edited
the manuscript and prepared the Figures. Atze
J. Bergsma and W.W.M. Pim Pijnappel provided the sec-
tions specifically on inborn errors of metabolism and
edited the manuscript.
ORCID
Annemieke Aartsma-Rus https://orcid.org/0000-0003-
1565-654X
REFERENCES
1. Stix G. Shutting down a gene. Antisense drug wins approval.
Sci Am. 1998;279(46):50.
2. Hair P, Cameron F, McKeage K. Mipomersen sodium: first
global approval. Drugs. 2013;73:487-493.
3. Aartsma-Rus A, Krieg AM. FDA approves Eteplirsen for
Duchenne muscular dystrophy: the next chapter in the
Eteplirsen saga. Nucl Acid Ther. 2017;27:1-3.
4. Aartsma-Rus A. FDA approval of Nusinersen for spinal muscu-
lar atrophy makes 2016 the year of splice modulating oligonu-
cleotides. Nucl Acid Ther. 2017;27:67-69.
5. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen
treatment for patients with hereditary transthyretin amyloid-
osis. N Engl J Med. 2018;379:22-31.
6. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran,
an RNAi therapeutic, for hereditary transthyretin amyloidosis.
N Engl J Med. 2018;379:11-21.
7. Hoy SM. Patisiran: first global approval. Drugs. 2018;78:1625-
1631.
8. Yang X, Lee SR, Choi YS, et al. Reduction in lipoprotein-
associated apoC-III levels following volanesorsen therapy:
phase 2 randomized trial results. J Lipid Res. 2016;57:
706-713.
9. Sardh E, Harper P, Balwani M, et al. Phase 1 trial of an RNA
interference therapy for acute intermittent porphyria. N Engl J
Med. 2019;380:549-558.
10. Roshmi RR, Yokota T. Viltolarsen for the treatment of
Duchenne muscular dystrophy. Drugs Today (Barc). 2019;55:
627-639.
11. Crooke ST. Molecular mechanisms of antisense oligonucleo-
tides. Nucl Acid Ther. 2017;27:70-77.
12. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted
therapeutics. Cell Metab. 2018;27:714-739.
13. Jarver P, O'Donovan L, Gait MJ. A chemical view of oligonu-
cleotides for exon skipping and related drug applications. Nucl
Acid Ther. 2014;24:37-47.
14. Eckstein F. Phosphorothioates, essential components of thera-
peutic oligonucleotides. Nucl Acid Ther. 2014;24:374-387.
15. Godfrey C, Desviat LR, Smedsrod B, et al. Delivery is key: les-
sons learnt from developing splice-switching antisense thera-
pies. EMBO Mol Med. 2017;9:545-557.
16. Goyenvalle A, Griffith G, Babbs A, et al. Functional correction
in mouse models of muscular dystrophy using exon-skipping
tricyclo-DNA oligomers. Nat Med. 2015;21:270-275.
17. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-
onset spinal muscular atrophy with nusinersen: a phase
2, open-label, dose-escalation study. Lancet (London, England).
2016;388:3017-3026.
18. Rigo F, Chun SJ, Norris DA, et al. Pharmacology of a central
nervous system delivered 2'-O-methoxyethyl-modified survival
of motor neuron splicing oligonucleotide in mice and non-
human primates. J Pharmacol Exp Ther. 2014;350:46-55.
19. Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles
enabling gene therapies: from concepts to clinical utility. Nucl
Acid Ther. 2018;28:146-157.
20. Nair JK, Willoughby JL, Chan A, et al. Multivalent N-
acetylgalactosamine-conjugated siRNA localizes in hepatocytes
and elicits robust RNAi-mediated gene silencing. J Am Chem
Soc. 2014;136:16958-16961.
21. Hartmann G. Nucleic acid immunity. Adv Immunol. 2017;133:
121-169.
22. Krieg AM. Mechanisms and applications of immune stimula-
tory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999;
1489:107-116.
23. Krieg AM, Matson S, Fisher E. Oligodeoxynucleotide modifica-
tions determine the magnitude of B cell stimulation by CpG
motifs. Antisense Nucleic Acid Drug Dev. 1996;6:133-139.
24. Frazier KS. Antisense oligonucleotide therapies: the promise
and the challenges from a toxicologic pathologist's perspective.
Toxicol Pathol. 2015;43:78-89.
25. Levin AA. A review of the issues in the pharmacokinetics and
toxicology of phosphorothioate antisense oligonucleotides. Bio-
chim Biophys Acta. 1999;1489:69-84.
26. Henry SP, Giclas PC, Leeds J, et al. Activation of the alternative
pathway of complement by a phosphorothioate oligonucleo-
tide: potential mechanism of action. J Pharmacol Exp Ther.
1997;281:810-816.
27. Sheehan JP, Phan TM. Phosphorothioate oligonucleotides
inhibit the intrinsic tenase complex by an allosteric mecha-
nism. Biochemistry. 2001;40:4980-4989.
28. Crooke ST, Baker BF, Witztum JL, et al. The effects of 2'-O-
Methoxyethyl containing antisense oligonucleotides on plate-
lets in human clinical trials. Nucl Acid Ther. 2017;27:121-129.
29. Levin AA. Treating disease at the RNA level with oligonucleo-
tides. N Engl J Med. 2019;380:57-70.
14 KUIJPER ET AL.
30. Hausen P, Stein H. Ribonuclease H. An enzyme degrading the
RNA moiety of DNA-RNA hybrids. Eur J Biochem. 1970;14:
278-283.
31. McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-
controlled trial of mipomersen in patients with severe hyper-
cholesterolemia receiving maximally tolerated lipid-lowering
therapy. PLoS One. 2012;7:e49006.
32. Won JI, Zhang J, Tecson KM, McCullough PA. Balancing low-
density lipoprotein cholesterol reduction and hepatotoxicity
with Lomitapide mesylate and mipomersen in patients with
homozygous familial hypercholesterolemia. Rev Cardiovasc
Med. 2017;18:21-28.
33. Doench JG, Petersen CP, Sharp PA. siRNAs can function as
miRNAs. Genes Dev. 2003;17:438-442.
34. Watts JK, Ockene IS. RNA interference for the masses? siRNA
targeting PCSK9 promises prevention of cardiovascular disease.
Nucl Acid Ther. 2020;30:1-3.
35. Spitali P, Aartsma-Rus A. Splice modulating therapies for
human disease. Cell. 2012;148:1085-1088.
36. Singh NN, Howell MD, Androphy EJ, Singh RN. How the dis-
covery of ISS-N1 led to the first medical therapy for spinal mus-
cular atrophy. Gene Ther. 2017;24:520-526.
37. Lefebvre S, Burglen L, Reboullet S, et al. Identification and
characterization of a spinal muscular atrophy-determining
gene. Cell. 1995;80:155-165.
38. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham
control in infantile-onset spinal muscular atrophy. N Engl J
Med. 2017;377:1723-1732.
39. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus
sham control in later-onset spinal muscular atrophy. N Engl J
Med. 2018;378:625-635.
40. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated
in infants during the presymptomatic stage of spinal muscular
atrophy: interim efficacy and safety results from the phase
2 NURTURE study. Neuromusclar Disord. 2019;29:842-856.
41. Schorling DC, Pechmann A, Kirschner J. Advances in treatment
of spinal muscular atrophy - new phenotypes, new challenges,
new implications for care. J Neuromuscular Dis. 2020;7:1-13.
42. Niks EH, Aartsma-Rus A. Exon skipping: a first in class strat-
egy for Duchenne muscular dystrophy. Expert Opin Biol Ther.
2017;17:225-236.
43. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized
oligonucleotide therapy for a rare genetic disease. N Engl J
Med. 2019;381:1644-1652.
44. Brasil S, Viecelli HM, Meili D, et al. Pseudoexon exclusion by
antisense therapy in 6-pyruvoyl-tetrahydropterin synthase defi-
ciency. Hum Mutat. 2011;32:1019-1027.
45. Agarwal S, Simon AR, Goel V, et al. Pharmacokinetics and
pharmacodynamics of the small interfering ribonucleic acid,
Givosiran, in patients with acute hepatic porphyria. Clin
Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1802.
46. Scott LJ. Givosiran: first approval. Drugs. 2020;80:335-339.
47. Hull V, Wang Y, Burns T, et al. Antisense oligonucleotide
reverses leukodystrophy in Canavan disease mice. Ann Neurol.
2020;87:480-485.
48. Vega AI, Perez-Cerda C, Desviat LR, Matthijs G, Ugarte M,
Perez B. Functional analysis of three splicing mutations identi-
fied in the PMM2 gene: toward a new therapy for congenital
disorder of glycosylation type Ia. Hum Mutat. 2009;30:795-803.
49. Oustric V, Manceau H, Ducamp S, et al. Antisense
oligonucleotide-based therapy in human erythropoietic prot-
oporphyria. Am J Hum Genet. 2014;94:611-617.
50. Palhais B, Dembic M, Sabaratnam R, et al. The prevalent deep
intronic c. 639+919 G>A GLA mutation causes pseudoexon
activation and Fabry disease by abolishing the binding of
hnRNPA1 and hnRNP A2/B1 to a splicing silencer. Mol Genet
Metab. 2016;119:258-269.
51. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of
apolipoprotein B and low-density lipoprotein cholesterol by
short-term administration of an antisense inhibitor of apolipo-
protein B. Circulation. 2006;114:1729-1735.
52. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipo-
protein B synthesis inhibitor, for lowering of LDL cholesterol
concentrations in patients with homozygous familial hyper-
cholesterolaemia: a randomised, double-blind, placebo-
controlled trial. Lancet (London, England). 2010;375:998-1006.
53. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis
inhibition with mipomersen in heterozygous familial hyper-
cholesterolemia: results of a randomized, double-blind,
placebo-controlled trial to assess efficacy and safety as add-on
therapy in patients with coronary artery disease. Circulation.
2012;126:2283-2292.
54. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apoli-
poprotein B synthesis inhibitor, lowers low-density lipoprotein
cholesterol in high-risk statin-intolerant patients: a random-
ized, double-blind, placebo-controlled trial. Eur Heart J. 2012;
33:1142-1149.
55. Flaim JD, Grundy JS, Baker BF, McGowan MP, Kastelein JJ.
Changes in mipomersen dosing regimen provide similar exposure
with improved tolerability in randomized placebo-controlled
study of healthy volunteers. J Am Heart Assoc. 2014;3:e000560.
56. Santos RD, Duell PB, East C, et al. Long-term efficacy and
safety of mipomersen in patients with familial hyper-
cholesterolaemia: 2-year interim results of an open-label exten-
sion. Eur Heart J. 2015;36:566-575.
57. Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S,
Kastelein JJP. Long-term mipomersen treatment is associated
with a reduction in cardiovascular events in patients with
familial hypercholesterolemia. J Clin Lipidol. 2016;10:1011-
1021.
58. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al.
Effect of an RNA interference drug on the synthesis of pro-
protein convertase subtilisin/kexin type 9 (PCSK9) and the con-
centration of serum LDL cholesterol in healthy volunteers: a
randomised, single-blind, placebo-controlled, phase 1 trial.
Lancet (London, England). 2014;383:60-68.
59. Bandyopadhyay D, Qureshi A, Ghosh S, et al. Safety and effi-
cacy of extremely low LDL-cholesterol levels and its prospects
in hyperlipidemia management. J Lipids. 2018;2018:8598054.
60. Chandra Ghosh G, Bandyopadhyay D, Ghosh RK, Mondal S,
Herzog E. Effectiveness and safety of Inclisiran, a novel long-
acting RNA therapeutic inhibitor of Proprotein convertase sub-
tilisin/kexin 9. Am J Cardiol. 2018;122:1272-1277.
61. Leiter LA, Teoh H, Kallend D, et al. Inclisiran lowers LDL-C
and PCSK9 irrespective of diabetes status: the ORION-1 ran-
domized clinical trial. Diabetes Care. 2019;42:173-176.
62. Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses
of Inclisiran on low-density lipoprotein cholesterol levels: one-
KUIJPER ET AL. 15
year follow-up of the ORION-1 randomized clinical trial. JAMA
Cardiol. 2019. https://doi.org/10.1001/jamacardio.2019.3502.
63. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment
of heterozygous familial hypercholesterolemia. N Engl J Med.
2020;382:1520-1530.
64. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of
Inclisiran in patients with elevated LDL cholesterol. N Engl J
Med. 2020;382:1507-1519.
65. Diaz-Font A, Chabas A, Grinberg D, Vilageliu L. RNAi-
mediated inhibition of the glucosylceramide synthase (GCS)
gene: a preliminary study towards a therapeutic strategy for
Gaucher disease and other glycosphingolipid storage diseases.
Blood Cells Mol Dis. 2006;37:197-203.
66. Sanaker PS, Toompuu M, McClorey G, Bindoff LA. Antisense
oligonucleotide corrects splice abnormality in hereditary myop-
athy with lactic acidosis. Gene. 2012;494:231-236.
67. Holmes-Hampton GP, Crooks DR, Haller RG, et al. Use of anti-
sense oligonucleotides to correct the splicing error in ISCU
myopathy patient cell lines. Hum Mol Genet. 2016;25:5178-5187.
68. Rincon A, Aguado C, Desviat LR, Sanchez-Alcudia R, Ugarte M,
Perez B. Propionic and methylmalonic acidemia: antisense ther-
apeutics for intronic variations causing aberrantly spliced mes-
senger RNA. Am J Hum Genet. 2007;81:1262-1270.
69. Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson D, Byers S.
Gene silencing of EXTL2 and EXTL3 as a substrate deprivation
therapy for heparan sulphate storing mucopolysaccharidoses.
Eur J Hum Genet. 2010;18:194-199.
70. Matos L, Goncalves V, Pinto E, et al. Data in support of a func-
tional analysis of splicing mutations in the IDS gene and the
use of antisense oligonucleotides to exploit an alternative ther-
apy for MPS II. Data Brief. 2015;5:810-817.
71. Matos L, Goncalves V, Pinto E, et al. Functional analysis of
splicing mutations in the IDS gene and the use of antisense oli-
gonucleotides to exploit an alternative therapy for MPS II. Bio-
chim Biophys Acta. 2015;1852:2712-2721.
72. Dziedzic D, Wegrzyn G, Jakobkiewicz-Banecka J. Impairment
of glycosaminoglycan synthesis in mucopolysaccharidosis
type IIIA cells by using siRNA: a potential therapeutic
approach for Sanfilippo disease. Eur J Hum Genet. 2010;18:
200-205.
73. Rodriguez-Pascau L, Coll MJ, Vilageliu L, Grinberg D. Anti-
sense oligonucleotide treatment for a pseudoexon-generating
mutation in the NPC1 gene causing Niemann-Pick type C dis-
ease. Hum Mutat. 2009;30:E993-E1001.
74. Vetrini F, Tammaro R, Bondanza S, et al. Aberrant splicing in
the ocular albinism type 1 gene (OA1/GPR143) is corrected
in vitro by morpholino antisense oligonucleotides. Hum Mutat.
2006;27:420-426.
75. Belanger AM, Przybylska M, Gefteas E, et al. Inhibiting neutral
amino acid transport for the treatment of phenylketonuria. JCI
Insight. 2018;3:121762
76. Clayton NP, Nelson CA, Weeden T, et al. Antisense
oligonucleotide-mediated suppression of muscle glycogen
synthase 1 synthesis as an approach for substrate reduction
therapy of Pompe disease.Mol Ther Nucl Acids. 2014;3:e206.
77. Bergsma AJ, In't Groen SL, Verheijen FW, van der Ploeg AT,
Pijnappel W. From cryptic toward canonical pre-mRNA
splicing in Pompe disease: a pipeline for the development of
antisense oligonucleotides. Mol Ther Nucl Acids. 2016;5:e361.
78. van der Wal E, Bergsma AJ, Pijnenburg JM, van der Ploeg AT,
Pijnappel W. Antisense oligonucleotides promote exon inclu-
sion and correct the common c.-32-13T>G GAA splicing vari-
ant in Pompe disease. Mol Ther Nucl Acids. 2017;7:90-100.
79. van der Wal E, Bergsma AJ, van Gestel TJM, et al. GAA deficiency
in Pompe disease is alleviated by exon inclusion in iPSC-derived
skeletal muscle cells.Mol Ther Nucl Acids. 2017b;7:101-115.
80. Goina E, Peruzzo P, Bembi B, Dardis A, Buratti E. Glycogen
reduction in myotubes of late-onset Pompe disease patients
using antisense technology. Mol Ther. 2017;25:2117-2128.
81. Goina E, Musco L, Dardis A, Buratti E. Assessment of the functional
impact on the pre-mRNA splicing process of 28 nucleotide variants
associated with Pompe disease in GAA exon 2 and their recovery
using antisense technology.HumMutat. 2019;40:2121-2130.
82. Dutta C, Avitahl-Curtis N, Pursell N, et al. Inhibition of
glycolate oxidase with dicer-substrate siRNA reduces calcium
oxalate deposition in a mouse model of primary hyperoxaluria
type 1.Mol Ther. 2016;24:770-778.
83. Lai C, Pursell N, Gierut J, et al. Specific inhibition of hepatic
lactate dehydrogenase reduces oxalate production in mouse
models of primary hyperoxaluria. Mol Ther. 2018;26:1983-1995.
84. Milliner DS, McGregor TL, Thompson A, et al. Endpoints for
clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol.
2020;CJN.13821119.
85. Li X, Knight J, Fargue S, et al. Metabolism of (13)
C5-hydroxyproline in mouse models of primary hyperoxaluria
and its inhibition by RNAi therapeutics targeting liver glycolate
oxidase and hydroxyproline dehydrogenase. Biochim Biophys
Acta. 2016;1862:233-239.
86. Liebow A, Li X, Racie T, et al. An investigational RNAi therapeutic
targeting glycolate oxidase reduces oxalate production in models of
primary hyperoxaluria. J Am Soc Nephrol. 2017;28:494-503.
87. Wood KD, Holmes RP, Erbe D, Liebow A, Fargue S, Knight J.
Reduction in urinary oxalate excretion in mouse models of pri-
mary Hyperoxaluria by RNA interference inhibition of liver
lactate dehydrogenase activity. Biochim Biophys Acta Mol Basis
Dis. 2019;1865:2203-2209.
88. Perez B, Gutierrez-Solana LG, Verdu A, et al. Clinical, bio-
chemical, and molecular studies in pyridoxine-dependent epi-
lepsy. Antisense therapy as possible new therapeutic option.
Epilepsia. 2013;54:239-248.
89. Perez B, Vilageliu L, Grinberg D, Desviat LR. Antisense medi-
ated splicing modulation for inherited metabolic diseases: chal-
lenges for delivery. Nucl Acid Ther. 2014;24:48-56.
90. Coutinho MF, Santos JI, Alves S. Less is more: substrate reduc-
tion therapy for lysosomal storage disorders. Int J Mol Sci.
2016;17:E1065
91. Austin CP, Cutillo CM, Lau LPL, et al. Future of rare diseases
research 2017-2027: an IRDiRC perspective. Clin Transl Sci.
2018;11:21-27.
How to cite this article: Kuijper EC, Bergsma AJ,
Pijnappel WP, Aartsma-Rus A. Opportunities and
challenges for antisense oligonucleotide therapies.
J Inherit Metab Dis. 2020;1–16. https://doi.org/10.
1002/jimd.12251
16 KUIJPER ET AL.
